CENTESSA PHARMACEUTICALS-ADR Share Price Today: Live Updates & Key Insights

CENTESSA PHARMACEUTICALS-ADR share price today is $26.6269, up -4.52%. The stock opened at $28.335 against the previous close of $28.34, with an intraday high of $28.5629 and low of $26.76.

CENTESSA PHARMACEUTICALS-ADR Share Price Chart

CENTESSA PHARMACEUTICALS-ADR

us-stock
To Invest in {{usstockname}}
us-stock

CENTESSA PHARMACEUTICALS-ADR Share Price Performance

$26.6269 -0.0452(-4.52%) CNTA at 23 Mar 2026 12:30 PM Biotechnology
Lowest Today 26.76
Highest Today 28.5629
Today’s Open 28.335
Prev. Close 28.34
52 Week High 30.58
52 Week Low 9.60
Day’s Range: Low 26.76 High 28.5629
52-Week Range: Low 9.60 High 30.58
1 day return -
1 Week return -4.34
1 month return +6.4
3 month return +6.66
6 month return +15.78
1 year return +62.62
3 year return +612.1
5 year return +21.48
10 year return -

CENTESSA PHARMACEUTICALS-ADR Institutional Holdings

Medicxi Ventures Management (Jersey) Ltd 13.51

venBio Select Advisor LLC 9.85

Adage Capital Partners Gp LLC 7.63

Index Venture Life Associates VI Ltd 6.74

FMR Inc 6.06

General Atlantic Llc 4.14

HHG PLC 3.66

Farallon Capital Management, L.L.C. 3.64

T. Rowe Price Associates, Inc. 3.25

Siren, L.L.C. 2.72

TCG Crossover Management, LLC 2.12

EcoR1 Capital, LLC 2.11

Perceptive Advisors LLC 2.10

Franklin Resources Inc 1.73

First Light Asset Management, LLC 1.54

Fidelity Select Biotechnology 1.50

BRAIDWELL LP 1.48

Cormorant Asset Management, LLC 1.30

T. Rowe Price Health Sciences 1.28

Millennium Management LLC 1.27

RTW INVESTMENTS, LLC 1.21

Federated Hermes Inc 1.18

Fidelity Select Health Care 1.12

Federated Hermes Kaufmann Growth 0.84

Federated Hermes Kaufmann R 0.84

Fidelity Contrafund 0.83

American Funds SMALLCAP World A 0.77

Federated Hermes Kaufmann Small Cap A 0.73

Federated Hermes Kaufmann Small Cap Grow 0.73

Franklin Biotechnology Discv A(acc)USD 0.72

Janus Henderson Triton D 0.59

Janus Henderson US SMID Cap Growth 0.59

American Century Small Cap Growth Inv 0.58

American Century U.S. Small Cap Growth 0.58

Fidelity Advisor Health Care I 0.58

Strategic Advisers Fidelity US TtlStk 0.50

Fidelity VIP Mid Cap Initial 0.48

Franklin Biotechnology Discovery A 0.42

Franklin US Small Cap Growth Equity 0.41

Franklin Small Cap Growth Adv 0.40

CENTESSA PHARMACEUTICALS-ADR Market Status

Strong Buy: 7

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

CENTESSA PHARMACEUTICALS-ADR Fundamentals

Market Cap 3952.81 M

PB Ratio 13.2638

PE Ratio 0.0

Enterprise Value 3872.05 M

Total Assets 576.80 M

Volume 573489

CENTESSA PHARMACEUTICALS-ADR Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:null 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-157421000 -157.4M, FY22:-216207000 -216.2M, FY21:-381071000 -381.1M, FY20:-11041000 -11.0M, FY19:-5284000 -5.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:15000000 15.0M, Q4/2024:null 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-228674 -0.2M, Q1/2025:15000000 15.0M, Q4/2024:null 0.0M, Q3/2024:-236264 -0.2M

Quarterly Net worth Q3/2025:-54891000 -54.9M, Q2/2025:-50343000 -50.3M, Q1/2025:-26135000 -26.1M, Q4/2024:-42566000 -42.6M, Q3/2024:-43816000 -43.8M

About CENTESSA PHARMACEUTICALS-ADR & investment objective

Company Information Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Organisation Biotechnology

Employees 114

Industry Biotechnology

CEO Dr. Mario Alberto Accardi Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

CENTESSA PHARMACEUTICALS-ADR FAQs

What is the share price of CENTESSA PHARMACEUTICALS-ADR today?

The current share price of CENTESSA PHARMACEUTICALS-ADR is $26.6269.

Can I buy CENTESSA PHARMACEUTICALS-ADR shares in India?

Yes, Indian investors can buy CENTESSA PHARMACEUTICALS-ADR shares by opening an international trading and demat account with Motilal Oswal.

How to buy CENTESSA PHARMACEUTICALS-ADR shares in India?

You can easily invest in CENTESSA PHARMACEUTICALS-ADR shares from India by:

Can I buy fractional shares of CENTESSA PHARMACEUTICALS-ADR?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of CENTESSA PHARMACEUTICALS-ADR?

CENTESSA PHARMACEUTICALS-ADR has a market cap of $3952.81 M.

In which sector does CENTESSA PHARMACEUTICALS-ADR belong?

CENTESSA PHARMACEUTICALS-ADR operates in the Biotechnology sector.

What documents are required to invest in CENTESSA PHARMACEUTICALS-ADR stocks?

To invest, you typically need:

What is the PE and PB ratio of CENTESSA PHARMACEUTICALS-ADR?

The PE ratio of CENTESSA PHARMACEUTICALS-ADR is N/A and the PB ratio is 13.26.